George Mason University President Angel Cabrera said more restrictive immigration policies could threaten the future of regional and national biotechnology industries.
“It is critical for universities to act both as producers of [science, technology, engineering and math] talent and as magnets for top STEM faculty and researchers from around the world. That is our biggest role in the ecosystem,” Cabrera said. “When we mess with immigration policy, our whole system of science and innovation is at stake.
Is your employee compensation package competitive?
Help us help you. Complete the 2018 BHCR Industry Compensation Survey by June 1, 2018 to receive an anonymized summary of salaries and benefits specific to positions in biohealth and to this region. A pdf version of the survey is available here or you can use the online version of the survey to complete your information. All company specific information will be kept confidential. This survey is a joint project among BioHealth Innovation, WorkSource Montgomery, and UMBC-Shady Grove’s Industrial Organizational Pyschology Program. If you or your Human Resources colleagues have any questions about the survey, please contact BHI@BioHealthInnovation.org.
Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, today announced the close of a $60 million USD Series B funding round. The financing will accelerate growth of Corvidia’s ongoing clinical programs, expand scientific and market access capabilities and explore new treatment areas.
The Emmes Corporation today announced the creation of an internship program in which the company will offer one fellow from Egypt’s Children Cancer Hospital an internship to gain training and experience in clinical research. Under the new program, one fellow will be selected each year to travel to Emmes’ headquarters in Rockville, Maryland, to work with its clinical research experts. The duration of each internship will be determined on a case-by-case basis.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory approval of PartoSureTM , which is a novel test for assessing the risk of spontaneous preterm birth in patients with symptoms of preterm labor. The pre-market approval of PartoSure by the U.S. Food and Drug Administration (FDA) follows successful uptake of the rapid, accurate test in more than 35 countries across Europe, the Middle East, Asia and Latin America. U.S. commercialization of the PartoSure test is expected to begin in 2018.
The first quarter of 2018 saw a decline in investments, given that global deal activity decreased by 4 percent. Despite the fewer deals, global investment reached $46.5 billion, invested across 2,884 deals. The data was revealed as part of a larger report titled Money Tree, put together by CB Insights and PricewaterhouseCoopers, with focus on the latest trends in venture capital funding globally.
He is a walking Rolodex of some of the nation’s most high-powered business leaders. And he’s the reason many startups feel they’ve gotten a leg up in an otherwise crushing entrepreneurial race.
More than a dozen biotech companies or researchers from the Maryland biotech cluster, which some have also dubbed ‘Vaccine Alley’, were among the most recognized finalists at this year’s Vaccine Industry Excellence (ViE) Awards in Washington, DC at the World Vaccine Conference. In fact, 15 out of the 54 finalists, or 27%. were from right here in Maryland. This year’s conference was held in Washington, DC so could this have been a case of home court advantage? Probably not. More than likely it’s because this region holds 20% of the top influencers worldwide in vaccine development.
On Tuesday, April 3, 2018 TEDCO Incubation Challenge finalist FounderTrac had their first Demo Day at Host Sponsor Loews Annapolis Hotel. After a 12 week, rigorous program 10 FounderTrac finalists pitched to a standing room only atrium of over 200 attendees. Over 50 angel investors and venture capitalists were in attendance creating an energy at the event that truly represents the essence of entrepreneurship. Tami Howie, CEO of the Maryland Technology Council says, “We had a huge number of high quality investors attend our showcase to see the amazing growth of our companies over the last 12 weeks of our FounderTrac program.”
Are you involved in the fight against drug resistant bacteria? Between June 1 and June 8th, organizations seeking funding to advance antimicrobial technologies (diagnostics, therapeutics or devices) will have the opportunity to submit Expressions of Interest (EOI) to CARB-X. CARB-X is dedicated to accelerating global antibacterial innovation through targeted funding of focused projects. Only technologies specifically focused on the Pathogens outlined in the CARB-X 2018 Funding Round 2 Scope will be considered. Now is the time to beginning preparing your EOI. More information is available on the CARB-X website: http://www.carb-x.org/application
MaxCyte, the global cell-based medicines and life sciences company, announced today that it has appointed Claudio Dansky Ullmann, MD, a 25+-year expert in clinical oncology and pharmaceutical research, as its Chief Medical Officer (CMO). In his new role, Dr. Dansky Ullmann is responsible for overseeing clinical development of MaxCyte’s CARMA™ drug development program as the company’s first candidate, MCY-M11, is expected to enter the clinic this year.
Patients dealing with hypotension, or dangerously low blood pressure, can now be treated with a drug initially developed by George Washington University researcher Lakhmir Chawla from the School of Medicine and Health Sciences and the GW Medical Faculty Associates.
Prince William County today congratulated three science start-ups – ISOThrive, LLC, Virongy, LLC and Ceres Nanosciences, Inc., – on recent business successes leading from the Prince William Science Accelerator.
New York investment firm Deerfield Management is looking to bring more drugs, medical devices and health care products to market by partnering with academic institutions like Johns Hopkins University.
Chinese investors are pumping money into US drug startups as Beijing seeks to become a global leader in new medicines, adding to a flood of cash flowing to groundbreaking health firms.
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a proud member of Manufacturing USA® is pleased to welcome Genentech, Celgene, Merck, MilliporeSigma and EMD Serono (the U.S. businesses of Merck KGaA, Darmstadt, Germany), among others, to its growing membership base.
Towson University celebrated the start of construction on the new science complex with a groundbreaking ceremony on the top floor of the Glen Garage April 17.
Construction for the new science complex began in fall 2017, but the ceremony marked the University officially breaking ground on the project.
We hear a lot these days about the so-called “rise of the rest”—the ascent of second-tier American cities such as Pittsburgh, St. Louis, Detroit, and Nashville as challengers to the established tech capitals of the Bay Area, New York, Boston, and Seattle. But the reality is that the rise of the rest is happening mainly in cities outside of the United States.
